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abstract
Inﬂuenza and respiratory syncytial virus (RSV) infections are responsible for considerable morbidity,
mortality and health-care resource use. For the Netherlands, we estimated age and risk-group speciﬁc
numbers of antibiotics, otologicals and cardiovascular prescriptions per 10,000 person-years during peri-
ods with elevated activity of inﬂuenza or RSV, and compared these with peri-season rates. Data were
taken from the University of Groningen in-house prescription database (www.iadb.nl) and virological
surveillance for the period 1998–2006. During inﬂuenza and RSV periods excess antibiotic prescriptions
were estimated for all age groups. In the age groups 0–1 and 2–4 years, excess antibiotic prescriptions
during periods with elevated RSV activity (65% and 59% of peri-seasonal rates) exceeded the surpluses
estimated during the inﬂuenza-activity periods (24% and 34% of peri-seasonal rates) while for otologicals
excess prescriptions were higher for inﬂuenza (22% and 27%) than for RSV (14% and 17%). Among persons
of 50 years and older, notably those without medical high-risk conditions, excess prescriptions for car-
diovascularmedicationswereestimatedduringtheinﬂuenzaperiodsatapproximately10%(thiswasalso
already seen in persons aged 45–49). Our results may have implications for inﬂuenza vaccination poli-
cies. In particular, extension of inﬂuenza vaccination to groups of non-elderly adults and young children
may lower excess prescriptions during these inﬂuenza periods for all three types of drug prescriptions
investigated.
© 2008 Elsevier Ltd. All rights reserved.
1. Introduction
In many countries annual inﬂuenza vaccination has been rec-
ommended for the elderly and persons with high-risk medical
conditions. In the Netherlands until 2007, the age-threshold for
such vaccination was 65 years for non-high-risk groups. In 2008,
this threshold was lowered to include all persons aged 60 years
and older [1]. In addition in the Netherlands, all high-risk groups
are vaccinated, including individuals suffering from chronic condi-
tions,respiratorydiseases,cardiacdiseases,diabetesmellitus,renal
failure,thosebeingimmunocompromisedandindividualsagedless
than 18 years of age on chronic salicylates use [1]. Vaccination rates
among these high-risk groups under 65 years of age ranged from
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66% to 83% in the Netherlands in 2005 [2]. Persons of 65 years
and older with a medical indication showed higher vaccination
coverages compared to those of the same age without such an indi-
cation,at90%and76%in2005,respectively[2].Inﬂuenzamaycause
acutebronchitisandpneumoniainhigh-riskgroupsandelderlyand
mayleadtoexacerbationsofunderlyingchronicmedicalconditions
such as cardiovascular diseases, asthma and diabetes, potentially
leading to hospitalisations and death. Prevention of inﬂuenza
infection by vaccination is of high importance for these groups
with an increased risk for complications from inﬂuenza infection
[3–5].
Although some countries recommend routine inﬂuenza vacci-
nationamongchildrenaged6monthsto2years,clinicaldataabout
the impact of vaccination are limited [1,6]. Yet, vaccination of all
healthy children in this age group could be cost-effective or even
cost-saving for some societal settings [6]. In the Netherlands, uni-
versal inﬂuenza vaccination of such children is in debate, however
yet the vaccine efﬁcacy and effectiveness for this speciﬁc age group
is not considered to be sufﬁciently demonstrated [7–9]. Therefore,
the Dutch Health Council concluded in 2007, not yet to start with
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inﬂuenza vaccination of these groups [1]. Comparable conclusions
were made for healthy children aged 2 years and older. Although
vaccination was shown to be effective for these children, inﬂuenza
was considered not to cause serious morbidity or mortality in the
Netherlands in those groups [1].
Next to inﬂuenza virus A and B, respiratory syncytial virus (RSV)
has been shown to cause similar types of complications, including
complications in the respiratory tract. RSV is often recognized as a
cause of morbidity and mortality among both children and adults,
contributing to a major burden of illness [10–17]. No preventive
vaccine is yet marketed for RSV.
In general, it is difﬁcult to estimate the individual contributions
of inﬂuenza and RSV to the aforementioned disease burdens accu-
rately as inﬂuenza and RSV co-circulate during winter seasons. For
burdenofdiseaseoftenthelabelInﬂuenzaLikeIllnesses(ILI)iscon-
sidered to primarily comprise disease due to inﬂuenza infections,
howeverknowntopotentiallycomprisevariousotheragentsinclu-
siveRSV,withtheidentiﬁcationoftherelativecontributionsofboth
virusesbeingstronglyhampered[18–21].Inparticular,evenfurther
viral agents, such as adeno-, parainﬂuenza-, and corona-viruses
may contribute to the burden of ILI [21,22]. For exactly analysing
the burdens of disease of inﬂuenza and RSV separately, which is
the goal of our current paper, ILI is therefore an inappropriate con-
cept. Therefore, we chose to analyse isolates exactly related to the
respective causal agents.
GiventhepotentialcomplicationsofinﬂuenzaandRSV,onemay
expect excess health-care resource utilization during epidemics
[23].Studiesestimatingsuchexcessresourceutilizationhaveprevi-
ously been directed to hospital admissions and GP-visits, but there
is as yet hardly any information on the association between the
occurrence of inﬂuenza and RSV and the use of medications among
the general population [24]. Drug-use for speciﬁc complications of
inﬂuenza and RSV could certainly temporarily be elevated. In par-
ticular, prescriptions for antibiotics, otologicals and cardiovascular
medication may be elevated, dispensed for otitis media, cardiac
complications, respiratory illness and other pulmonary complica-
tions.Toaddressthistopic,weinvestigatedtheassociationbetween
weekly reported RSV and inﬂuenza isolates in the Netherlands
and the weekly number of prescription drugs dispensed by Dutch
pharmacies, in particular those for antibiotics, otologicals and car-
diovascular drugs.
From the preventive point of view, high inﬂuenza-associated
drug-use may justify more extended use of preventive measures,
such as inﬂuenza vaccination. In particular, it may enhance the
health-economic proﬁle of extended inﬂuenza vaccination for
currently yet unvaccinated groups. As such, our research may con-
tribute to discussions as to whether, for example, young children
should be vaccinated or whether the age limit of the vaccination
program should be lowered further.
2. Data and methods
2.1. Virological surveillance and study period
During 1998–2006, the Dutch Working Group on Clinical Virol-
ogygathereddatafrom20laboratoriesthroughouttheNetherlands,
testingclinicalspecimensforrespiratoryviruses,includingRSVand
inﬂuenza A and B. The number of patients who tested positive for
RSV or inﬂuenza was reported on a weekly basis. In the absence
of any drastic changes in recruiting and testing of specimens the
weekly time series can validly be conceived as representing the
actual time trend, without requiring any corrections to be applied
on the data. To exclude weekly random ﬂuctuations a 3-week mov-
ing average was used for presentation (Fig. 1) and for deﬁning the
speciﬁc weeks exhibiting elevated activity for inﬂuenza and RSV.
Two methods for deﬁning weeks with elevated activity of
inﬂuenza and RSV were applied. The ﬁrst method deﬁned a week
with elevated activity as one with a moving average of more than
two times the gross overall average weekly number from week 40
in1998onwardstoweek39of2006(week1obviouslybeingthe1st
week in January; week 40 generally being considered as the start of
the inﬂuenza season). Following Jansen et al., the second method
deﬁned the weeks with elevated activity as those weeks from any
period of at least 2 consecutive weeks, with each individual week
accounting for over 5% of the season’s total number of inﬂuenza-
or RSV-positive specimens [18]. From both methods, it appeared
that periods consisting of a number of subsequent weeks resulted,
rather than individual weeks or short periods of, for example, 2
weeks only. Such periods would be expected – and were indeed
found – to be between week 40 and week 20 in the next year (the
non-summer season) [18,25].
The weeks that contained both inﬂuenza and RSV activity were
excluded for deﬁning the periods with elevated activity, given the
difﬁculty to separate out the individual inﬂuences in these weeks
with combined activity. As a result, only those weeks with either
elevated inﬂuenza or RSV were analyzed. Furthermore, a peri-
season was deﬁned, containing the weeks from week 40 up to and
including week 20 of the next year, which did not belong to the
inﬂuenza or the RSV periods (seasons). The weeks from week 21 up
to and including week 39 were labelled “summer”.
2.2. Population
Information on drug-use in the population was provided
by a University of Groningen in-house prescription database
(www.iadb.nl). The database iadb.nl contains prescription, demo-
graphic and population data of 500,000 persons adherent to 50
pharmacies in the North and East of the Netherlands. For analytical
purposes,theprescriptionsweredividedover5-yearagecategories.
Fig. 1. Number of RSV- and inﬂuenza-positive specimens (3-week moving averages), the number prescriptions for antibiotics and otologicals and ﬁrst prescriptions for
cardiovascular medication, all for all age groups aggregated.M.D.M. Assink et al. / Vaccine 27 (2009) 1119–1126 1121
The age category 0–4 years was further divided in the ages 0–1
and 2–4, to enable analysis of infants separately. For presentation
the following categorization was applied: 0–1, 2–4, 5–19, 20–49,
50–54, 55–59, 60–64 and 65+. The exact age of any person was
determined every year on the 1st of October, close to the period in
which in the Netherlands the invitations for inﬂuenza vaccination
for risk groups are sent out by the GPs, supposedly just prior to the
season with increased risk for inﬂuenza epidemics from October
onwards to May. The annual total population sizes were based on
estimatesforthe1stofJanuarybythelocalauthoritiesintheplaces
where the pharmacies are located.
Persons who received one of the studied drugs were divided in
high-risk and low-risk groups for inﬂuenza. The respective popula-
tions belonging to both groups were estimated using prescriptions
as a proxy, for those medications that are consistent with high-
risk indications as speciﬁed by the Dutch Health Council [1] and
the Dutch GPs (http://nhg.artsennet.nl) and that are uniquely pre-
scribed for these indications [26]. For example, dornase alfa, a drug
prescribed for cystic ﬁbrosis, was included to deﬁne persons with
respiratory diseases. Other medications for cystic ﬁbrosis, such as
acetylcysteine, are also prescribed for cough and were therefore
not included. Table 1 lists these drugs speciﬁcally. For heart med-
ication, diuretic sulfonamides were included. Other diuretics used
for lowering blood pressure were excluded, as high-blood pressure
is not a high-risk identiﬁed condition. Furthermore, only calcium
antagonists with ATC-code C08D were included as only these are
assumed to have cardiac effects. Beta blockers and RAAS system
agentswereexcludedasthesearenotexclusivelyprescribedforcar-
diac diseases, but also, for example, for high-blood pressure only.
For renal diseases, medication for the treatment of hyperkalemia
and hyperphosphatemia, and antianemic preparations and sulfon-
amides were included as these are often prescribed for dialysis
or renal insufﬁciency. To identify immunocompromised patients,
immunosuppressives were included, which can be prescribed, for
example, for patients after organ transplantation. Also HIV medi-
cations were included as also HIV-patients are listed as high-risk
group.
As mentioned, in the Netherlands, inﬂuenza vaccination is rec-
ommendedtothoseattheincreasedriskofcomplicationsbasedon
speciﬁc medical conditions. To determine which speciﬁc patients
should be labelled as belonging to the high-risk group, the recom-
mendations of the Dutch Health Council [1] and the guidelines of
the Dutch GPs (http://nhg.artsennet.nl, accessed 24th September
2007) for inﬂuenza and high-risk indications were used [26].I n
particular, persons were labelled belonging to the high-risk group
if they had two or more prescriptions from the same group of med-
ications included on the list, on two different dates in the year
before the ﬁrst of October. The latter was supposed to guarantee
that the condition would be chronic in that speciﬁc year (note that
a person’s risk status may change from year to year). The popu-
lation size of the high-risk group was subsequently determined
on the 1st of October by counting the number of high-risk per-
sons in iadb.nl; the rest of the population was assumed at low
risk.
2.3. Classiﬁcation of prescriptions
Wespeciﬁcallydirectedouranalysistothedruggroupsofantibi-
otics, otologicals and cardiovascular drugs, as these drugs may be
considered for those complications of both viral infections that
have yet been published in the scientiﬁc literature [23,24,27–29].
From iadb.nl, prescriptions of antibiotics (ATC-code J01), otologi-
cals (ATC-code S02) and medications for the cardiovascular system
(ATC-code C) were selected.
Antibiotics are commonly prescribed for the treatment of acute
otitis media (AOM), in particular for young children in which AOM
accounts for approximately half of all antibiotics courses deliv-
ered [30–32]. Otologicals may also be prescribed for AOM, despite
that they are not recommended by the Dutch College of General
Practitioners (NHG) [29]. In addition, more than average numbers
of antibiotics may be prescribed for elderly persons with ILI dur-
ing periods with elevated activity, as particularly this group may
develop acute respiratory illnesses (for example, pneumonia) as
a complication of the viral infection (trimethoprim and nitrofu-
rantoin were excluded from the analysis as they are prescribed
primarily for urinary tract infections) [33]. For antibiotics and oto-
logicals both initial and next prescriptions within the same year
were considered.
Table 1
Medications considered to be speciﬁc for high-risk indications.
Disease Medication ATC code
Respiratory diseases Drugs for obstructive airway diseases R03
Dornase alfa R05CB13
Tuberculosis medication J04A
Cardiac diseases Acetylsalicylic acid B01AC06
Carbasalate calcium B01AC08
Clopidogrel B01AC04
Organic nitrates C01DA
Antiarrhythmics C01B
Digoxin C01AA05
Diuretics: sulfonamides C03CA
Calcium channel blockers C08D
Diabetes Insulin (analogue) A10A
Blood glucose lowering medication A10B
Chronic renal disease Drugs for treatment of hyperkalemia and hyperphosphatemia V03AE
Other antianemic preparations B03XA
Erythropoietin B03XA01
Darbepoetin alfa B03XA02
Diuretics (sulfonamides only) C03CA
Immunocompromised Immunosuppressive agents L04
HIV-medication: direct acting antivirals J05A EFGX
Oral corticosteroids H02AB
Children below 18 years old who are taking long term salicylates Salicylic acid and derivates N02BA01
N02BA15
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Table 2
Exact weeks deﬁning periods with elevated activity.
Year Inﬂuenzaa (weeks) Inﬂuenzab (weeks) RSVa (weeks) RSVb (weeks) Peri-season (weeks) Summer (weeks)
1998–1999 1–14 1–14 44–53 44–53 40–43, 15–20 21–39
1999–2000 51–9 4–9 47–3 47–50 40–46, 10–20 21–39
2000–2001 4–6 – 49–7 49–3, 7 40–48, 8–20 21–39
2001–2002 6–16 6–16 48–3 48–3 40–47, 4–5, 17–20 21–39
2002–2003 9–15 9–15 45–2 45–2 40–44, 3–8, 16–20 21–39
2003–2004 50–5 – 49–7 49, 6–7 40–48, 8–20 21–39
2004–2005 3–14 6–14 49–5 49–2 40–48, 15–20 21–39
2005–2006 9–15 9–15 48–7 48–7 40–47, 8, 16–20 21–39
Total number of weeks 73 54 81 62 131 152
a Inclusive weeks with combined activity of both inﬂuenza and RSV.
b Weeks with combined activity excluded, period used for actual analysis.
It is well known that inﬂuenza-related complications are more
prevalent among persons with cardiovascular and other chronic
diseasesthaninpersonswithoutsuchunderlyingconditions[4,34].
In persons of 65 years and older with high-risk conditions an
increased rate of hospitalisation for cardiac problems has been
reported [17]. Some further recent studies suggest that there
might also be an association between cardiovascular problems and
inﬂuenza epidemics among groups without any cardiovascular his-
tory yet, such as the elderly or even among those aged below 65
years of age [23,35]. For analysing cardiovascular medications, only
ﬁrst prescriptions were considered as our current interest was to
investigatewhethertheviralinfectionswererelatedtonewcardio-
vascular disease and/or exacerbations of existing – yet untreated –
background cardiovascular conditions, rather than identify chronic
medications for cardiovascular diseases (note that chronic car-
diovascular medication use was used as a criterion for assigning
persons to the high-risk group). A prescription was deﬁned as a
ﬁrst prescription when a person had not had a prescription for the
samedrugoradrugfromthesamesubgroupintheyearbeforethat
speciﬁc prescription.
2.4. Statistics
After the various periods of elevated activity were determined,
thenumberofprescriptionsintheweeksbelongingtotheinﬂuenza
andRSVperiods/seasonswerecomparedtothenumberofprescrip-
tions in the peri-season. For comparative purposes also results for
comparingwiththesummerseasonarepresented.Thiswasdonein
everyagegroupforthetotalpopulation,thehigh-riskgroupandthe
low-risk group. Incidence rates were calculated and corresponding
95%-conﬁdence intervals were estimated [36]. The incidence rate
(I)wascalculatedastheweeklynumberofprescriptionsper10,000
person-years:
I =
n 
i=1
Pi
(Nn)/52
× 10,000
with Pi being the number of prescriptions in week i of a season
(inﬂuenza, RSV, peri or summer), n the number of weeks of that
speciﬁc period of interest and N the population size (per age group,
forhighriskorforlowrisk).Thedivisionby52istotransferperson-
week estimates into person-years (for 2 years 53 instead of 52 had
tobeused).MicrosoftOfﬁceExcel2003wasusedforprocessingthe
data, calculations and graphics.
3. Results
3.1. Periods with elevated activity of inﬂuenza and RSV
During the study period, the average weekly number of
inﬂuenza-positive and RSV-positive specimens were 11.77 and
36.90, respectively. The ﬁrst method for deﬁning the periods of
elevated activity using two times the average number of iso-
lates per week as a lower limit (23.54 for inﬂuenza and 73.80
for RSV) resulted in Table 2, showing the weeks which were
labelled as belonging to the inﬂuenza, RSV, peri- and summer
periods.
The second method, deﬁning the periods with elevated activity
asatleasttwoconsecutiveweeksinwhicheachweekaccountedfor
over 5% of the season’s total number of RSV- or inﬂuenza-positive
specimens yielded comparable results (data not shown). Hereafter,
only for those results where both methods differed, the results of
both methods are presented otherwise the results of only the ﬁrst
method are shown.
Obviously, periods with elevated activity and the peri-season
changed from year to year, both in length (the summer season of
course always ranged from week 21 up to and including week 39 of
the next year). In some years overlap in inﬂuenza and RSV activity
weeks were seen, in which case weeks were excluded. In fact, in
the years 2000–2001 and 2003–2004 there was no inﬂuenza-only
period left (although 4 weeks remained in 2000–2001 if the 2nd
method was used).
Table 3
Person-years during periods of elevated activity per age group for the total popula-
tion, high-risk group and low-risk group.
Age group Inﬂuenza RSV Peri-season Summer
Total population
0–1 11499 13452 28651 33044
2–4 17248 20177 42977 49566
5–19 86692 100726 213531 246961
20–49 238725 277212 589120 680702
50–54 32349 37811 80150 92574
55–59 27200 32184 67792 78353
60–64 20977 24538 51696 59863
65+ 66848 77534 164202 190012
High-risk group
0–1 393 454 970 1118
2–4 668 774 1662 1914
5–19 2785 3246 6882 7954
20–49 10871 12823 27188 31349
50–54 4047 4795 10180 11726
55–59 4838 5830 12331 14187
60–64 5243 6210 13052 15089
65+ 30724 36035 76397 88201
Low-risk group
0–1 11106 12998 27681 31926
2–4 16581 19403 41315 47652
5–19 83907 97480 206650 239007
20–49 227853 264389 561932 649353
50–54 28301 33015 69970 80848
55–59 22362 26354 55461 64166
60–64 15734 18328 38644 44774
65+ 36124 41499 87806 101811M.D.M. Assink et al. / Vaccine 27 (2009) 1119–1126 1123
Table 4
Excessdrugprescriptionsfortheperiodswithelevatedactivitycomparedtotheperi-season,shownasnumbersofprescriptionsper10,000person-years(as%ofperi-seasonal
levels).
Seasons 0–1 years 2–4 years 5–19 years 20–49 years 50–54 years 55–59 years 60–64 years 65+ years
Antibiotics
RSV total 3791(65%) 2326(59%) 248(15%) 236(10%) 264(8.9%) 431(13%) 572(15%) 669(13%)
Inﬂuenza total 1397(24%) 1328(34%) 417(25%) 407(18%) 461(15%) 615(18%) 796(21%) 761(14%)
Inﬂuenza high risk – – 819(20%) 761(13%) 717(12%) 827(13%) 1059(16%) 846(12%)
Inﬂuenza low risk – – 404(25%) 393(18%) 432(17%) 586(22%) 721(24%) 722(19%)
Otologicals
RSV total 79(14%) 90(17%) aa a a aa
Inﬂuenza total 126(22%) 142(27%) aa a a aa
Cardiovascular medication
RSV total – – aa a a aa
Inﬂuenza total – – ab 110(8.7%) 122(7.4%) 159(7.4%) 196(6.3%)
Inﬂuenza high risk – – aa a a a 130(3.3%)
Inﬂuenza low risk – – ab 110(11%) 170(13%) 163(10%) 269(11%)
The number of persons was insufﬁcient for valid estimation.
a Result not statistically signiﬁcant.
b Although borderline signiﬁcant not shown here for the whole age-group as further 5-year age-group speciﬁc analyses revealed that signiﬁcance was related only to a
signiﬁcant and clinically relevant surplus for the age category 45–49: 113.12 (12.95%) and 122.78 (17.06%) for the total population and low-risk group, respectively.
3.2. Population
Table 3 presents the number of person-years for the inﬂuenza,
RSV, peri-season and summer periods per age and risk group. For
infants and children aged 2–4, the high-risk group was very small
with 393 person-years in the inﬂuenza period and 454 person-
years for the RSV period, and therefore only the ﬁgures for both
low- and high-risk groups taken together were used for these ages.
Furthermore, in all age groups the number of person-years in the
high-risk group was lower than the numbers in the low-risk group.
We also note, as expected, that the older age groups contained rel-
atively more person-years in the high-risk group than the younger
age groups.
3.3. Isolates and prescriptions
Fig. 1 shows the number of positive ﬁndings for RSV and
inﬂuenza per week. The annual inﬂuenza and RSV epidemics are
clearly seen, as is the overlap in some years. Also the number of
(ﬁrst) prescriptions per 10,000 persons for antibiotics, otologicals
andcardiovascularmedicationisplottedforthetotalpopulation.In
particular, for antibiotics a clear pattern is visible in which during
inﬂuenza and RSV activity periods a peak in antibiotic use occurs.
Additionally, we notice that in the younger age groups amoxicillin
was the mostly prescribed antibiotic, whereas from the age group
5–19 onwards other antibiotics were mostly prescribed (data not
shown).
3.4. Comparative statistics
The excess prescriptions per 10,000 person-years during the
inﬂuenza and RSV periods are presented in Table 4, as compared to
the peri-season. We noted that both methods used for estimating
the activity periods showed similar results.
Thenumberofprescriptionsforantibioticswassigniﬁcantlyele-
vated during the activity periods in each age group. For the age
groups 0–1 and 2–4, excess prescriptions were highest in the RSV
periods, in the older age groups surpluses were higher during the
inﬂuenza periods. For inﬂuenza, the low-risk group showed higher
excess prescriptions compared to the high-risk group. Prescription
of otologicals was signiﬁcantly elevated during the periods of ele-
vated activity, however only in the youngest age groups of infants
and children aged 2–4 years. In contrast to antibiotics, excess pre-
scriptions were higher during inﬂuenza periods than during RSV
periods.
For ﬁrst cardiovascular medications, the prescription rate in the
RSV periods was lower than in the peri-season, although not signif-
icant. During the inﬂuenza period, higher prescription rates were
found for those aged 50 years and older. When the age group of
20–49 was analyzed in 5-year age categories separately, also a sig-
niﬁcant difference for the age category 45–49 was seen.
Fig. 2 shows the prescription rates per 10,000 person-years
and conﬁdence intervals for selected aggregated age groups for
the different periods per year separately, as well as for the aggre-
gated years. The incidence rates of antibiotics were increased
during the inﬂuenza and the RSV periods in comparison with
the peri-season (and the summer season). This increase was
noticeable for every year. For otologicals, the incidence rate was
increased but the conﬁdence intervals were wide and therefore
not every year rendered a statistically signiﬁcant difference during
the inﬂuenza and RSV periods. For ﬁrst cardiovascular prescrip-
tions also an increase was noticeable during inﬂuenza periods
as compared to the peri-season, but again not for every year
a signiﬁcant difference was found. Finally, we note from Fig. 1
that elevations in the inﬂuenza and RSV periods are not nec-
essarily followed by relatively lower levels in the peri- and/or
summer seasons, suggesting that surpluses detected are actual
extra prescriptions that are not “neutralized” by subsequent dips
in prescriptions.
4. Discussion
Statistically signiﬁcant excess antibiotic prescriptions during
periods with elevated activity of inﬂuenza and RSV were found
for both viruses in all age groups, each year investigated and irre-
spective of the method used for exactly deﬁning the inﬂuenza
or RSV activity periods. For otologicals during both inﬂuenza and
RSV-active periods, statistically signiﬁcant surpluses were found in
young children only. Oppositely, excess cardiovascular drug pre-
scriptions were identiﬁed in adults and elderly in periods with
elevated inﬂuenza activity.
We generally found a tendency for higher percentages of sur-
pluses in low-risk groups than in high-risk groups. For antibiotics
andcardiovasculardrugs,thiscanprobablybeexplainedbythefact
that individuals belonging to a high-risk group have a higher likeli-
hood of being vaccinated against inﬂuenza, lowering the chance of
infection and secondary bacterial or cardiovascular complications.
This tendency also applied to low-risk elderly as compared to high-
risk elderly, despite the fact that this whole group is recommended
for vaccination.1124 M.D.M. Assink et al. / Vaccine 27 (2009) 1119–1126
Fig. 2. Incidence rates and conﬁdence intervals for prescriptions of antibiotics for all ages (A), otologicals for ages 0–4 (B) and cardiovascular medicatio nf o ra g e s4 5a n d
older (C).
Some choices in our research should be noted. Speciﬁcally, the
lower limit for the weekly moving-averaged number of isolates for
weekstobelabelledasactivewaschosenbytwodifferentmethods.
Theﬁrstusedacut-offoftwotimestheaveragenumberofinﬂuenza
or RSV isolates per week. This limit was chosen to achieve contin-
uous periods per year of weeks subsequently labelled as active, i.e.
to guarantee epidemic periods rather than ﬂuctuations. The second
methodwasusedtobeinconcordancewithapreviouslyperformed
Dutchstudyusingtheweekswhichaccountedfor5%ormoreofthe
season’s total number of inﬂuenza or RSV isolates [18]. In general,
both methods resulted in similar results.
By using the inﬂuenza and RSV activity periods that excluded
weeks of combined activity, possible major inﬂuence by the pres-
ence of the respective other virus was reduced. However, the
exclusion of weeks in which both inﬂuenza and RS viruses were
active was only necessary in 4 out of the years included in thisM.D.M. Assink et al. / Vaccine 27 (2009) 1119–1126 1125
analysis. Also, in methodology excluded weeks were not included
in counting person-years, so the effect of excluding those weeks
maybelimited.Yet,possibleinﬂuenceofanyotherrespiratoryvirus
obviously remains present. However, the impact of these viruses
is probably limited, as they may have long periods of marginally
increased activity rather than a clear seasonal pattern [18]. Fur-
thermore, complications are expected to be milder compared to
inﬂuenza and RSV infection [18].
We compared our data for the activity periods with the peri-
season, which provided a more conservative estimation of the
surplusesthanifwewouldhavecomparedwiththesummerperiod.
Yet, some underestimation of the surpluses may be introduced in
thisway.Wedofeel,however,thatcomparisonwiththeperi-season
is most appropriate, as other potential inﬂuences concerning the
climate and possible other viruses that circulate in non-summer
periods are probably comparable between the peri-season and the
activity periods.
Every year, RSV-positive specimens reached a relatively small
and intensive peak around week 52. Earlier studies have shown
similartendencies,withRSVisolatespeakingeveryyeararoundthe
same time [14,15,37]. This suggests the presence of potential com-
mon strict seasonal factors which might increase both the number
ofisolatesandprescriptions;howeverprobablynotinvalidatingthe
associations and surpluses found in our analyses, which are truly
seen and are in line with other studies [14,15,37].
Persons were labelled as belonging to the high-risk group based
on speciﬁc medication proﬁles. In particular, persons belonging to
thehigh-riskgroupwereselectedbasedonprescriptionsthatcorre-
sponded rather uniquely to the high-risk indications. Prescriptions
potentially meant for other indications, not labelled as high risk,
were consistently excluded. Still, it is possible that these selection
criteria unjustly labelled individuals as belonging to the high-risk
groups. Also, some individuals may have been incorrectly excluded
and labelled as non-high-risk.
Finally, one may hypothesize that excess prescriptions are
merely shifts in time of extra prescriptions later to be outweighed
by dips in prescriptions (sometimes referred to as “the harvesting
effect”). Visual inspection of our data however did not give any rea-
son to support this hypothesis in our study. Additionally, a formal
statistical comparison of the number of prescriptions during the
peri-seasons and during the ﬁrst 5 weeks after the active seasons
did not show any peak-dip pattern (data not shown).
Previously, various investigations have been performed on the
associationbetweeninﬂuenzaandRSVepidemics,ontheonehand,
and hospitalisations, mortality and outpatient visits, on the other
[14,17,18,24,33,37–44]. Below, we brieﬂy compare the outcomes,
knowing that the validity of making such comparisons between
studies is limited due to differences in outcome measurement, sta-
tistical models, study period, and health-care system concerned.
Previously,onlyonestudyinvestigatedexcessantibioticusedur-
ing inﬂuenza-activity periods in the general population [24]. This
study did show that otherwise healthy children get more prescrip-
tions for antibiotics during these inﬂuenza periods. However, the
surplus reported was relatively low compared to our ﬁndings [24].
Twootherstudiesestimatedtheexcessantibioticprescriptionsdur-
ing both RSV and inﬂuenza-active seasons, focussing on speciﬁc
target groups [33,43]. The ﬁrst study focussed on patients suffering
from chronic lung disease, showing the highest surpluses for the
youngestagegroups[43].Thelatterstudyshowedhighersurpluses
due to inﬂuenza as compared to RSV for those living in nursing
homes [33]. Both results are in line with our ﬁndings for antibiotics
[33,43].
Several other studies indicate that, in general, both during
RSV and inﬂuenza-activity periods, infants and elderly show the
highest morbidity and mortality rates [14,18,24,37,39–44]. This is
certainlyinlinewithourﬁndingsonexcessantibioticandotological
prescriptions among the youngest age groups and cardiovascular
medication surpluses among the older age groups. In contrast to
otherstudieswhichshowedhighermorbidityandmortalityamong
the oldest age groups compared with non-elderly adults, our study
shows that the elevation in the prescriptions of antibiotics in the
oldestagegroups(65yearsofageandolder)isnothigherthaninthe
two younger age groups (55–59 and 60–64). Yet, if compared with
otheradultagegroups,asmallincreasecouldbeseen.Forinﬂuenza,
this slightly deviating ﬁnding compared to non-Dutch settings,
mightbeexplainedbythehighvaccinationcoverageamongelderly
in the Netherlands.
A recent Dutch study showed that RSV-related excess hospi-
talisations were considerably higher as compared to those due to
inﬂuenza [18]. Comparably, a study performed for England and
Wales showed greater excess rates for complications during RSV-
active periods among the youngest age groups as compared to
inﬂuenza; similar rates were found for all other age groups [37].
Fiveotherstudiesfocussingonexcessmorbidity,mortalityandhos-
pitalisation among children conﬁrmed these results, showing that
RSV was responsible for higher hospitalisation rates than inﬂuenza
[14,39–42].
For the Netherlands, Jansen et al. recently showed excess hospi-
talisation for cardiovascular complications among the 50–64 years
old,duringinﬂuenza-activeperiodsbutnotduringRSV-activeperi-
ods[18].Inlinewiththeirﬁndings,weshowedasigniﬁcantsurplus
in ﬁrst cardiovascular medication prescriptions during inﬂuenza-
active periods, but not during RSV-active periods for those aged 45
years and over. Elevated hospitalisation and prescription rates dur-
ing inﬂuenza periods in persons aged around 50 years and beyond
suggests that inﬂuenza may cause cardiovascular diseases or that
it may aggravate existing non-diagnosed cardiovascular diseases in
older adults. Another hypothesis explaining this increase might be
that increased cardiovascular problems during inﬂuenza periods
are related to the increased use of analgesics during those periods
to alleviate inﬂuenza symptoms [45]. Further research is deﬁnitely
needed into this topic.
Thus, in general, our results seem to be comparable with most
otherstudiesrelatingelevatedviralactivitytotheuseofhealth-care
resources, morbidity and mortality. All studies consistently show
that the highest excess rates for the youngest age groups are mostly
due to RSV, whereas those for inﬂuenza are seen in elderly.
Vaccination may prevent part of the excess prescriptions we
have found. For example, healthy children are not recommended to
be vaccinated against inﬂuenza in the Netherlands, while their vac-
cination might prevent part of the surplus prescriptions found for
this group. In particular, vaccination may prevent inﬂuenza infec-
tion and potential subsequent bacterial super infection(s) and thus
avert antibiotics prescribed for the prevention and treatment of
such bacterial super infections.
Additionally, reducing the prescription of antibiotics may also
be important from the perspective of limiting the development of
antibiotic resistance. Such reasoning could be an additional moti-
vation for vaccinating yet uncovered groups against inﬂuenza [23].
AneffectivevaccineagainstRSVmaypotentiallyevenpreventmore
antibiotic prescriptions, especially in young children [37]. Yet the
introduction of a vaccine again RSV is not expected in the very near
future [18].
5. Conclusions
During inﬂuenza- and RSV-active periods, elevations in antibi-
otic prescriptions were identiﬁed in all age groups. For otologicals,
such an elevation was shown in the age groups of 0–1 and 2–4
years, both during inﬂuenza-and RSV-active seasons. By vaccinat-
ing young children against inﬂuenza, a part of these prescriptions
for antibiotics and otologicals may be prevented.1126 M.D.M. Assink et al. / Vaccine 27 (2009) 1119–1126
In persons of 50 years and older an elevation of prescriptions for
cardiovascularmedicationwasshownduringtheperiodofelevated
inﬂuenza activity only, in particular for the low-risk population.
Also for antibiotic prescriptions, the excess found was higher in
the low-risk population than in the high-risk population, possibly
indicating the effectiveness of the vaccination program in the high-
risk group, in which a relatively high coverage rate is reached in the
Netherlands.
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